[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Thomas Jefferson University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":720},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,56,0,25,[9,53,92,125,174,196,229,248,273,301,322,351,371,399,425,447,477,496,526,557,584,606,633,677,695],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100564233","phase-1-tebentafusp-tebn-with-ldt-in-metastatic-um-100564233",false,"NCT06626516","Tebentafusp-tebn With LDT in Metastatic UM","A Phase I\u002FII Study of Tebentafusp-tebn in Combination With Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma","Inclusion Criteria\n\n1\\. Age ≥18 years of age 2. Histologically or cytologically confirmed metastatic uveal melanoma in the liver. Patients must have at least one measurable liver metastasis that is ≥ 10 mm in longest diameter by CT scan or MRI. Extra-hepatic disease is allowed. 3. Tumor Size Criteria: i. Part 1: Total volume of tumor must be \\\u003C 50% of the liver involvement by CT or MRI; M1a or M1b disease with largest tumor ≤ 5 cm ii. Part 2: M1b disease with largest tumor \\> 5 cm, M1c disease, or ≥ 50% liver involvement by CT or MRI 4. No prior systemic treatment with tebentafusp-tebn 5. Prior therapy: i. Part 1: Patients must be treatment naïve in the metastatic setting.\n\n1. Prior surgery or ablation for oligometastatic disease is allowable.\n2. Palliative radiation of non-target lesions also allowable. ii. Part 2: Patients may have had prior systemic therapy with chemotherapy, immunotherapy, or targeted therapy. They can also have had prior liver directed therapy including surgery, ablation, immunoembolization, or radioembolization. However cannot have had more than two prior lines of treatment total.\n\n6\\. HLA-A\\*0201 positive 7. ECOG performance status or 0 or 1 at the time of screening 8. Life expectancy of greater than 3 months as assessed by the investigator 9. Patients must have normal organ and bone marrow function as defined below:\n\n1. Platelet count ≥ 100,000\u002Fmm³\n2. Hemoglobin \\> 8.0g\u002FdL\n3. ANC ≥ 1500\n4. AST and\u002For ALT \\\u003C 3x upper limited of normal (ULN)\n5. Total bilirubin ≤ 2.0 mg\u002Fml\n6. Note: Patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and\u002For the principal investigator.\n7. PT\u002FPTT \\\u003C 1.5x ULN\n8. Creatinine clearance \\> 60mL\u002Fmin\n9. Potassium, magnesium, corrected calcium, and phosphate within normal laboratory parameters 10. Women must not be pregnant or breast-feeding. 11. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for the 6 months after the final dose of the study drug. Women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\n   12\\. Male patients treated or enrolled on this protocol must be surgically sterile or use double barrier contraception methods from enrollment through treatment, and for 6 months after completion of study therapy.\n\n   13\\. Ability to understand and the willingness to sign a written informed consent document.\n\n4.1.2 Exclusion Criteria\n\n1. Parts 1 and 2:\n\n   1. Failure to meet any of the criteria set forth in the Inclusion criteria section\n   2. History of prior tebentafusp-tebn use\n   3. Prior chemoembolization in Part 2 is not permitted\n   4. History of severe immediate or delayed hypersensitivity reaction to biologic drugs, monoclonal antibodies, iodinated contrast agent\n   5. Presence of symptomatic liver failure including ascites and hepatic encephalopathy\n   6. Presence of symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require corticosteroids within 21 days prior to initiation of study therapy. Patients with brain metastases may be eligible if lesions have been treated with local therapy and there is no evidence of CNS disease progression for at least 4 weeks as measured by MRI prior to first dose of study drug\n   7. History of another malignancy except for: 1) those who have been disease-free for 3 years prior to study treatment; 2) patients with a history of completely resected non-melanoma skin cancer; 3) patients with indolent secondary malignancies not requiring active therapy; 4) patients with completely resected carcinoma in situ. Consult the study Principal Investigator if unsure whether second malignancies meet the requirements specified above.\n   8. Major surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary)\n   9. Radiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass\n   10. No outstanding toxicities from prior therapies greater than Grade 1. Except for prior immune related side effects such as endocrinopathy that are managed with a stable dose of thyroid or steroid supplement.\n   11. Use of any investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study therapy and during the study.\n   12. Use of hematopoietic colony-stimulating growth factors (eg. G-CSF, GMCSF, M-CSF) within 14 days prior to study treatment initiation. An erythroid-stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment and the patient is not red blood cell transfusion dependent.\n   13. Known history of human immunodeficiency virus infection (HIV). Testing for HIV is not necessary unless clinically indicated\n   14. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Testing for HBV or HCV status is not necessary unless clinically indicated or if the patient has a history of HBV or HCV infection.\n   15. Patients receiving systemic steroid therapy or any immunosuppressive medication. Local steroid therapies (eg, otic, ophthalmic, intra-articular or inhaled medications) are acceptable.\n   16. History of bleeding diathesis\n   17. Pregnant, likely to become pregnant, or breastfeeding women\n   18. Uncontrolled concurrent illness, evaluated at investigator discretion\n   19. Biliary obstruction, biliary stent or prior biliary surgery except cholecystectomy, or any anatomic abnormalities that would interfere with immunoembolization or chemoembolization:\n   20. Patients with occlusion of the main portal vein\n   21. Inadequate collateral flow around an occluded portal vein as determined by angiography\n   22. Arteriovenous shunt identified on arteriography of the hepatic artery\n   23. Any medical condition that, in the Investigator's judgement, would prevent patient participation in the clinical study due to safety concerns, compliance with study procedures or interpretation of study results\n2. Part 1 Only:\n\n   1. History of severe immediate or delayed hypersensitivity reaction to GM-CSF","ALL","18 Years",{"count":20,"type":21},109,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study is a multicenter, open label phase I\u002F II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A\\*0201 positive patients with metastatic uveal melanoma. In Part 1 of the study, the Prinicipal Investigator will investigate the safety and efficacy of tebentafusp-tebn in combination with hepatic IE in patients with a low to moderate hepatic disease burden. In Part 2, the study will investigate the efficacy of tebentafusp-tebn in combination with TACE in patients with bulky hepatic disease.",[28],"Metastatic Uveal Melanoma",[30,31,32,33,34,35,36,37,38,39],"Uveal","uveal melanoma","metastatic uveal melanoma","melanoma","Liver-directed therapy","Liver-directed","Liver","liver-directed therapies","MUM","LDT","RECRUITING","2026-06-12",{"date":43,"type":44},"2026-06-16","ACTUAL",{"date":46,"type":44},"2025-10-15",{"date":48,"type":21},"2032-08",{"name":50,"class":51},"Thomas Jefferson University","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100547947","phase-2-neoadjuvant-tebentafusp-for-uveal-melanoma-100547947","NCT06414590","Neoadjuvant Tebentafusp for Uveal Melanoma","Neoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal Melanoma","Inclusion Criteria:\n\nIndividuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:\n\n1. Male or female patient age ≥ 18 years of age at the time of informed consent.\n2. Ability to provide and understand written informed consent prior to any study procedures.\n3. Willingness to undergo tumor biopsies at baseline and post-Tebentafusp treatment.\n4. Treatment naïve primary uveal melanoma with T3 or T4 category tumor size that are surgically unresectable (other than complete enucleation of eye).\n5. No surgical indication to completely remove the tumor without enucleation.\n6. Clinically or cytologically confirmed primary uveal melanoma.\n7. Participants must be HLA-A\\*02:01 positive.\n8. Predicted life expectancy of at least 12 weeks as estimated by investigator\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.\n10. All other relevant medical conditions must be well-managed and stable, in the opinion of the investigator, for at least 28 days prior to first administration of study drug.\n11. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Symptomatic uveal melanoma that requires immediate ophthalmological intervention such as enucleation.\n2. Evidence of metastatic disease.\n3. Previous treatment with Tebentafusp.\n4. Patients with any out-of-range laboratory values defined as:\n\n   * Serum creatinine \\> 1.5 x upper limit of normal (ULN) and\u002For creatinine clearance (calculated using Cockcroft-Gault Formula, or measured) \\\u003C 50 mL\u002Fminute\n   * Albumin \\\u003C 3.0 g\u002Fdl\n   * Total bilirubin \\>1.5 mg\u002FdL (or 1.3 x ULN). Patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and\u002For the principal investigator.\n   * Alanine aminotransferase \\> 1.5 x ULN\n   * Aspartate aminotransferase \\> 1.5 x ULN\n   * Absolute neutrophil count \\\u003C 1.0 x 109 \u002FL\n   * Absolute lymphocyte count \\\u003C 0.5 x 109 \u002FL\n   * Platelet count \\\u003C 100 x 109 \u002FL\n   * Hemoglobin \\\u003C 9.0 g\u002FdL\n   * Uncorrectable abnormal potassium, magnesium, corrected calcium or phosphate abnormality of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) \\> grade 1\n   * Morning cortisol \\\u003C lower limit of normal (unless the patient has asymptomatic adrenal insufficiency and is receiving stable replacement doses)\n5. History of severe hypersensitivity reactions (e.g., anaphylaxis) to other biologic drugs or monoclonal antibodies.\n6. Clinically significant cardiac disease or impaired cardiac function, including any of the following:\n\n   * Left Ventricular Ejection Fraction \\\u003C50%\n   * Clinically significant and\u002For uncontrolled heart disease such as congestive heart failure (New York Heart Association grade ≥ 2), uncontrolled hypertension, or clinically significant arrhythmia uncontrolled with medical treatment\n   * Acute myocardial infarction or unstable angina pectoris \\\u003C 6 months to Screening\n7. Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to the first dose of study drug.\n8. Participants with a history of human immunodeficiency virus (HIV) infection. NOTE: Testing is not required unless mandated by the local health authority. Participants with HIV infection may be eligible if ALL of the following are applicable:\n\n   1. Receiving an approved, stable, effective combination antiretroviral therapy regimen for \\> 3 months prior to the planned first study intervention. NOTE: please review Section 5.7 and consider whether any actions should be taken to minimize potential drug-drug interactions,\n   2. CD4 T cell count \\> 350 cells\u002Fµl,\n   3. CD4 T cell nadir (lowest historical count) \\> 200 cells\u002Fµl, and\n   4. Viral load confirmed as \\\u003C 50 copies\u002FmL during Screening.\n9. Participants with a known history of chronic viral infections as indicated below.\n\n   NOTE: Testing for hepatitis B virus (HBV) or hepatitis C virus (HCV) is not required unless mandated by the local health authority.\n   1. Known HBV infection defined as hepatitis B surface antigen reactive. NOTE: Participants with HBV infection on stable anti-viral therapy for \\> 4 weeks prior to the planned first study intervention and viral load confirmed as undetectable during Screening may be eligible.\n   2. Known active HCV infection defined as detectable HCV RNA (qualitative) infection. NOTE: History of HCV is not exclusionary if participants have received curative treatment and viral load is confirmed as undetectable during screening.\n10. Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type.\n11. Any medical condition that would, in the investigator's or Sponsor's judgement, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results.\n12. Patients receiving systemic steroid therapy or any other immunosuppressive medication at any dose level. Local steroid therapies (e.g., otic, ophthalmic, intra-articular or inhaled medications) are acceptable.\n13. Major surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary).\n14. Radiotherapy within 2 weeks of the first dose of study drug.\n15. Use of hematopoietic colony-stimulating growth factors (e.g., G-CSF, GMCSF, M-CSF) ≤ 2 weeks prior to start of study drug. An erythroid-stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment and the patient is not red blood cell transfusion dependent.\n16. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation).\n17. Women of child-bearing potential who are sexually active with a non-sterilized male partner, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective contraception during study treatment (defined in Section 8.4.7), and must agree to continue using such precautions for 6 months after the final dose of study drug; cessation of birth control after this point should be discussed with a responsible physician.\n18. Male patients must be surgically sterile or use double barrier contraception methods from enrolment through treatment and for 6 months following administration of the last dose of study drug.",{"count":61,"type":21},19,[25],"This is a prospective, single arm, phase II clinical trial of neoadjuvant Tebentafusp (KIMMTRAK®) in patients with locally advanced primary uveal melanoma. Patients must be HLA-A\\*02:01 with large, surgically unresectable (other than complete enucleation of the eye) primary uveal melanoma. The efficacy of this treatment will be assessed with the Simon's two stage design. The choice of design is guided by a desire to stop the trial early if the actual regression rate of primary uveal melanoma is 1% or lower.",[65],"Locally Advanced Unresectable Uveal Melanoma",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83],"Neoadjuvant Tebentafusp","Uveal Melanoma","Primary Uveal Melanoma","Neoadjuvant IMCgp100","gp100 peptide-HLA-directed CD3 T cell engager","HLA-A*02:01","KIMMTRAK®","Tebentafusp-tebn","IMCgp100","radioactive plaque therapy","enucleation","radioactive plaque","fine-needle aspiration","circulating tumor-derived DNA","Phase II","advanced primary uveal melanoma","Simon's two stage design","2026-06-10",{"date":41,"type":44},{"date":87,"type":44},"2025-09-05",{"date":89,"type":21},"2032-03",{"name":50,"class":51},2,{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":109,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100622725","phase-1-pacritinib-with-aza-for-upfront-myelodysplastic-syndrome-100622725","NCT07387354","Pacritinib With Aza for Upfront Myelodysplastic Syndrome","A Phase 1\u002F2 Study of Pacritinib in Combination With Azacitidine for the Treatment of IPSS-M Moderate Low to Very High Risk Myelodysplastic Syndrome","MDS","Inclusion Criteria:\n\n* Individuals must meet all of the following inclusion criteria to be eligible to participate in the study:\n\n  1. Patients must have histologic evidence of intermediate to high-risk myelodysplastic syndrome defined as having an IPSS-M score of moderate low, moderate high, high or very high risk. This will be assessed based on evaluations performed prior to screening for trial. Of note, the most recent evaluation pre-trial may be used which does not have to necessarily be at diagnosis.\n  2. Subjects must have recovered from the toxic effects of any prior chemotherapy to ≤ Grade 1 (except alopecia).\n  3. Required screening visit laboratory values: CrCL ≥45; total bilirubin \\\u003C2xULN except for patients with known Gilbert's disease; SGPT (ALT) ≤2xULN, PTT ≤1.5xULN.\n  4. Negative pregnancy test for women with child-bearing potential at screening visit.\n  5. Initial screening baseline QTc ≤480ms.\n  6. Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.\n  7. Patients must have an absolute neutrophil count of ≥750 to enroll in study, this must be achieved without the addition of growth factor medication.\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Any prior exposure to a hypomethylating agent (azacitidine or decitabine)\n  2. Any prior exposure to JAK2 inhibitor therapy (ie ruxolitinib or prior pacritinib therapy)\n  3. Any exposure within the past seven days of initiation of study treatment to a strong CYP3A inhibitor\u002Finducer.\n  4. Subjects must not be receiving any chemotherapy agents (except hydroxyurea) within the past thirty days.\n  5. Subjects must not be receiving growth factors (erythropoietin mimetics, granulocyte stimulating factor mimetics, thrombopoietin mimetics) for two weeks prior to enrollment bone marrow. Subjects may not receive growth factors for the duration of this study.\n  6. Subjects with a \"currently active\" second malignancy, other than curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix, resected incidental prostate cancer (staged pT2 with Gleason Score ≤ 6 and postoperative PSA \\\u003C0.5 ng\u002FmL), or other adequately treated carcinoma-in-situ are eligible. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 1 year.\n  7. Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure (NYHA class 2), myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.\n  8. Bleeding event grade \\>=2 (CTCAE 5.0) within prior three months unless provoked (e.g., by surgery or trauma)\n  9. Use of anticoagulant or antiplatelet agents within fourteen days prior to day one with the exception of low dose aspirin (81mg daily).\n  10. Subjects with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible.\n  11. Active or uncontrolled diarrhea or constipation.\n  12. Subjects must not have evidence of active disease in the CNS.\n  13. Subjects must not have received any investigational agents within fourteen days or five half-lives (whichever is longer) of study entry.\n  14. Subjects must not be pregnant or breastfeeding. Pregnancy tests must be obtained for all females of child-bearing potential. Pregnant or lactating patients are ineligible for this study due to the unknown human fetal or teratogenic toxicities of pacritinib. Males or women of childbearing potential may not participate unless they have agreed to use a highly effective contraceptive method (defined in section 10.4.4).\n  15. Subjects who have uncontrolled infection are not eligible. Patients must have any active infections under control. Fungal disease must be stable for at least two weeks before study entry.\n  16. Subjects with bacteremia must have documented negative blood cultures prior to study entry.\n  17. Subjects who are currently candidates for allogeneic transplantation, have a suitable donor, and are willing to undergo transplantation prior to study start.\n  18. Subjects who cannot hold a medication, over the counter, or supplemental product that in the investigator's opinion may put the patient at increased harm.",{"count":7,"type":21},[24,25],"This study will be conducted as a phase 1\u002F2 study of safety and preliminary efficacy of pacritinib in combination with azacitidine for IPSS-M moderate low to very high risk MDS. Phase one will be a 3 + 3 design to assess the dose for the phase two portion. The phase two portion will employ a simon min-max two-stage design whereby fifteen patients will be enrolled in the first stage then ten more if at least two patients in stage one have a response. The dosing of pacritinib for the phase two study will be based on the phase one findings. Standard dosing of azacitidine will be used. A correlative study will be conducted in conjunction with the trial where the investigators will measure whole blood collected pre-treatment and at four days post-treatment to measure intracellular flow and phosflow to detect JAK\u002FSTAT, NF-κβ, and AKT\u002FmTOR signaling in patient samples and how treatment affects these pathways.",[104,98,105,106,107,108],"Myelodysplastic Syndromes","Myelodysplastic Syndrome, Unclassifiable","Hematologic Diseases","Bone Marrow Disease","Myeloproliferative Neoplasm",[110,111,112,113,114,115,116],"Pacritinib","Azacitidine","IPSS-M","JAK\u002FSTAT","JAK\u002FIRAK1","NF-κβ","Myelodysplastic Syndrome","NOT_YET_RECRUITING","2026-06-08",{"date":84,"type":44},{"date":121,"type":21},"2026-07",{"date":123,"type":21},"2027-01",{"name":50,"class":51},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":144,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":52},"100604152","phase-2-y-90-treatment-response-using-transarterial-radioembolization-100604152","NCT07145801","Y-90 Treatment Response Using Transarterial Radioembolization","Contrast-Enhanced Ultrasound Evaluation of Radioembolization Treatment Response","TARE","Inclusion Criteria:\n\n* Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound.\n* Be at least 18 years of age.\n* Be medically stable.\n* If a female of child-bearing age, must have a negative pregnancy test.\n* Have signed Informed Consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.\n* Patients with known sensitivities to the components of Lumason.\n* Patients with known sensitivities to the components of Sonazoid.",{"count":134,"type":21},30,[25],"This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing cause of cancer mortality in the United States. TARE is recommended for 15-25% of HCC patients. Treatment response is generally evaluated using contrast-enhanced CT or MRI 1-2 months and 4-6 months post-TARE. Although TARE is an effective therapy, assessment of treatment response using CT\u002FMRI is challenging because CT\u002FMRI frequently diagnoses tumor response as equivocal or non-progressing for up to 6 months post-TARE based on LI-RADS criteria. This delay in diagnosing tumor viability subsequently delays needed retreatment and can even serve as a barrier to transplantation. Our prior work in HCC locoregional therapy has shown CEUS provides improved sensitivity in detecting viable tumor following transarterial chemoembolization relative to traditional CT\u002FMRI. Therefore, the investigators propose to evaluate both qualitative and quantitative CEUS as a tool for evaluating HCC post-TARE at similar time points of clinically recommended cross-sectional imaging, while also investigating the role of Kupffer phase imaging.\n\nThe investigators plan to enroll a total of 30 patients scheduled for TARE of a treatment naïve HCC over an 18-month period, allowing for a minimum of 6 months follow up. Patients will undergo a CEUS examination within two weeks of their first two clinically indicated CT\u002FMRI exams (obtained at Jefferson 1-2 months and 4-6 months post TARE). In patients retreated prior to their 4-6 month MRI, CEUS may also be performed in the absence of the MRI at this time point but prior to retreatment. Patients will be recruited across six major hospitals within the Jefferson Health Enterprise. Those eligible for participation will be identified by project co-investigators and contacted by the study coordinator to discuss participation and to explain the study. The patient will be given time to consider the risks and benefits of the study and ask questions about participation. If agreeable, the patient will then arrange with the project coordinator to come to Jefferson's center city campus to sign consent and take part in the research study.",[138,139,140,141,142,143],"HCC","Hepatocellular Carcinoma","Liver Cancer","Hepatic Neoplasm","Primary Liver Cancer","Liver Neoplasm",[145,131,146,147,148,149,138,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167],"transarterial radioembolization","CEUS","contrast-enhanced ultrasound","hepatocellular","carcinoma","hepatocellular carcinoma (HCC)","liver cancer","liver tumors","liver lesions","microbubbles","liver parenchyma","liver imaging","HCC locoregional therapy","Ultrasound","Kupffer","Yttrium-90","tumor viability","time intensity curves","parametric maps","microbubble destruction","bolus contrast injection","CEUS biomarker","Y90 TARE",{"date":84,"type":44},{"date":170,"type":44},"2025-09-11",{"date":172,"type":21},"2027-06-30",{"name":50,"class":51},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":181,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":193,"leadSponsor":195,"locationsCount":91},"100517994","phase-3-multiparametric-ultrasound-for-the-diagnosis-of-clinically-significant-prostate-cancer-100517994","NCT06024772","Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer","Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)","Inclusion Criteria:\n\n* Subject must be scheduled for a prostate biopsy, based on an elevated PSA (\\> 3.0ng\u002Fml) per most recent National Comprehensive Cancer Network (NCCN) guidelines, elevated PSA velocity (\\> 0.75ng\u002Fml\u002Fyear), or abnormal digital rectal examination\n* Subject must be able and willing to give written informed consent for a contrast enhanced ultrasound study of the prostate including the additional study biopsies\n* Subject must be a male at least 18 years of age when informed consent is obtained\n\nExclusion Criteria:\n\n* Participant in a clinical trial involving an investigational drug within the past 30 days\n* Patients with known or suspected hypersensitivity to perflutren, polyethylene glycol (PEG), or any other component of Definity\n* Previous treatment for prostate cancer, including hormone therapy\n* Clinically unstable, severely ill, or moribund as per treating physician","MALE",{"count":183,"type":21},300,[185],"PHASE3","This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.",[188],"Prostate Carcinoma","2026-06-03",{"date":191,"type":44},"2026-06-05",{"date":121,"type":21},{"date":194,"type":21},"2027-02",{"name":50,"class":51},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":204,"sex":205,"minAge":18,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":91},"100518892","late-cerclage-in-high-risk-pregnancies-latch-100518892","NCT06036446","LATe Cerclage in High-risk Pregnancies (LATCH)","Cervical Cerclage for Short Cervix at 24-26 Weeks of Gestation: a Randomized Controlled Trial","LATCH","Inclusion Criteria:\n\n* 18-50 years old, pregnant, assigned female at birth\n* Singleton pregnancy\n* TVU CL ≤25mm between 24 0\u002F7 - 26 6\u002F7 weeks of gestation\n\nExclusion Criteria:\n\n* Initial multifetal gestation with subsequent multifetal pregnancy reduction, or selective fetal termination performed \\>14 weeks, or cotwin pregnancy loss diagnosed \\>14 weeks\n* Cerclage in situ\n* Preterm labor, defined as painful regular uterine contractions and change in cervical dilation\n* PPROM\n* Active vaginal bleeding\n* Suspected intraamniotic infection\n* Major fetal structural abnormality or chromosomal disorder\n* Placenta previa or accreta\n* Other contraindication to cerclage placement\n* Participation in another clinical trial related to preterm birth prevention, cerclage, or progesterone",true,"FEMALE","50 Years",{"count":208,"type":21},329,[210],"NA","The goal of this clinical trial is to determine whether cervical cerclage reduces the risk of preterm birth in patients with a short transvaginal ultrasound (TVU) cervical length (CL) ≤25mm between 24 0\u002F7-26 6\u002F7 weeks.",[213],"Premature Birth",[215,216,217,218,219,220],"Cervical length","Short cervix","Shortened cervix","Prematurity","Preterm birth","Viability","2026-05-27",{"date":223,"type":44},"2026-05-29",{"date":225,"type":44},"2023-11-10",{"date":227,"type":21},"2029-02",{"name":50,"class":51},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":52},"100304609","assessment-of-multi-level-interventions-to-improve-adherence-to-oral-medications-in-cancer-patients-100304609","NCT03245411","Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients","A Randomized, Controlled Trial to Assess Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients in a Socioeconomically Disadvantaged Community","Inclusion Criteria:\n\n* All patients on oral chemotherapeutic agents\n* Clinical diagnosis of stage IV breast cancer\n* Clinical diagnosis of stage III and IV colorectal cancer (not receiving concurrent radiation therapy)\n* Clinical diagnosis of stage IV non-small cell lung cancer\n* Clinical diagnosis of stage IV renal cell carcinoma\n* Clinical diagnosis of stage IV ovarian carcinoma\n* Clinical diagnosis of multiple myeloma\n* Clinical diagnosis of chronic myelogenous leukemia on TKI\n* Clinical diagnosis of myelodysplastic syndrome on Lenalidomide\n* Adjuvant treatment for Gastro Intestinal Stromal Tumor\n* Clinical diagnosis of chronic Lymphocytic Leukemia\n* Clinical diagnosis of metastatic Prostate cancer\n* Clinical diagnosis of hepatocellular Carcinoma\n* Clinical diagnosis of stage IV Melanoma\n* Clinical diagnosis of myelofibrosis\u002Fmyeloproliferative neoplasms\n* Age \\>18 years\n* ECOG Performance Status \\\u003C3\n\nExclusion Criteria:\n\n* ECOG Performance Status of 3 and above\n* Concurrent chemo radiation\n* Non-English speaker\n* Clinical diagnosis of dementia, or otherwise unable to give informed consent.\n* History of non-compliance (defined as the history of 2 or more missed appointments in the clinic).\n* Pregnant patients\n* Nursing Home Patients\n* Incarcerated",{"count":237,"type":21},110,[210],"Einstein Medical Center in Philadelphia serves a diverse group of the patient population. The majority of patients have a diverse cultural background, low literacy, and poor social-economic status. Medication adherence for chronic medical problems is in a range of 40-70%. Medication adherence among patients on oral anti-cancer therapy is not studied in detail. The main objective is to study medication adherence to oral anticancer agents in patients with low literacy and poor socio-economic status.",[241],"Cancer",{"date":223,"type":44},{"date":244,"type":44},"2017-07-20",{"date":246,"type":21},"2026-12-31",{"name":50,"class":51},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":91},"100639656","phase-2-periprosthetic-joint-infection-bubble-study-100639656","NCT07599865","Periprosthetic Joint Infection Bubble Study","Using Ultrasound and Microbubbles to Augment Antibiotic Efficiency Against Periprosthetic Joint Infections","PJI","Inclusion Criteria:\n\n* Be at least 18 years of age\n* Be medically stable\n* If female of child-bearing potential, must have a negative pregnancy test\n* Be conscious and able to comply with study procedures\n* Have read and signed the IRB-approved Informed Consent form for participating in the study\n* For Cohort 1, be scheduled for one- or two-stage exchange arthroplasty revision surgery for PJI of the knee\n* For Cohort 2, be scheduled for DAIR revision surgery for PJI of the knee\n\nExclusion Criteria:\n\n* Females who are pregnant or nursing\n* Patients currently on chemotherapy requiring systemic treatment\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable\n* Patients with a history of anaphylactic allergy to perflutren or any other components of Definity\n* Patients with a history of failed one- or two-stage revision for infection\n* Patients for which placement of a surgical drain is contraindicated\n* Patients in protected classes (e.g., prisoners)",{"count":257,"type":21},100,[25],"Patients with an infected knee replacement will receive their standard of care surgical treatment of the infection, with and without additional ultrasound microbubble treatment (randomly divided 50\u002F50 in the active and control groups). Subjects in the active group will receive a local bolus injection of antibiotics and ultrasound-active microbubbles within 24 hours of their revision surgery. The fundamental hypothesis is that a decrease in re-infection rates of at least 24% can be achieved in the active group relative to controls.",[261],"Periprosthetic Joint Infection (PJI)",[263,264],"Periprosthetic knee infection","ultrasound-triggered microbubble destruction","2026-05-14",{"date":267,"type":44},"2026-05-20",{"date":269,"type":21},"2026-06",{"date":271,"type":21},"2030-06",{"name":50,"class":51},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":91},"100624816","radiotherapy-for-refractory-hidradenitis-suppurativa-100624816","NCT07414550","Radiotherapy for Refractory Hidradenitis Suppurativa","Radiotherapy for Treatment of Recalcitrant Hidradenitis Suppurativa (RADIANT-SUPPoRT)","RADIANTSUPPoRT","Inclusion Criteria:\n\n* Male or female subjects between the age of 18 or older with moderate or severe HS (Hurley Stage II or III) with bilateral axillary disease of approximately equivalent disease severity will be included.\n* Patients on topical and\u002For systemic HS medications for at least 1 month will continue maintenance treatment throughout the study period as per standard of care.\n* Patients willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnancy - Women of childbearing potential must use trial approved birth control and obtain a negative pregnancy test 7 days prior to radiotherapy CT simulation.\n* Severe autoimmune conditions including lupus, scleroderma and mixed connective tissue disease\n* Poorly controlled diabetes per physician discretion, HIV, Hepatitis B\u002FC.\n* Prior therapeutic radiotherapy.\n* Active malignancy.\n* Contraindication to radiotherapy as determined by treating radiation oncologist.\n* Patients who began new systemic treatment for their HS \\\u003C1 month prior to enrollment in trial\n* History of photosensitivity disorders or prior radiation sensitization syndromes\n* Any contraindication to radiotherapy as determined by the treating radiation oncologist.",{"count":282,"type":21},10,[210],"The goal of this clinical trial is to learn if high-dose radiotherapy can provide sustained disease relief in moderate to severe, treatment resistant Hidradenitis suppurativa patients; could include any of the following: any sex\u002Fgender, and those greater then 18 years old. The main question\\[s\\] it aims to answer are:\n\nOutcome measure 1: Will radiotherapy change the number of inflammatory nodules, abscesses, and draining sinus tracts in the treated axilla compared with the untreated axilla? Outcome measure 2: Will radiotherapy positively change a patient's quality of life, pain levels and symptom burden?\n\nParticipants will receive radiotherapy to one axilla affected by hidradenitis suppurativa. The contralateral axilla will not receive radiotherapy and will continue receiving the standard treatment regimen.\n\nParticipants will...\n\n* Attend a baseline dermatology skin evaluation, complete multiple surveys and an optional participation in a biopsy\n* Attend multiple radiation sessions over 5 weeks\n* Attend 2 follow up visits with dermatology for skin evaluation, complete follow up surveys, and an optional biopsy.",[286],"Hidradenitis Suppurativa (HS)",[288,289,290,291,292],"Hidradenitis suppurativa","HS","Radiotherapy","Radiation","Treatment resistant","2026-05-12",{"date":295,"type":44},"2026-05-15",{"date":297,"type":21},"2026-05-01",{"date":299,"type":21},"2028-03-01",{"name":50,"class":51},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":204,"sex":181,"minAge":18,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":309,"phases":4,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":52},"100487448","extending-prostate-genetic-awareness-navigation-and-delivery-the-expand-network-100487448","NCT05627219","Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network","Peer Genetic Coaches for Enhancing Genetic Testing Awareness, Navigation, and Delivery Among African American Men With Metastatic Prostate Cancer, The EXPAND Network","Inclusion Criteria:\n\n* AIM 1: Are 18 years old or older\n* AIM 1: Are able to read and speak English comfortably\n* AIM 1: Men who have experience with both prostate cancer (PCA) and genetic counseling and testing will be a priority for training, as well as men who have considerable peer education or navigation experience\n* AIM 2: Are 18 years old or older\n* AIM 2: Are African American\n* AIM 2: Are able to read and speak English comfortably\n* AIM 2: Men who meet any one of the following criteria: (1) metastatic prostate cancer; (2) prostate cancer with high-risk features (T3 or higher, Gleason 8 or higher, node positive disease); (3) with or without a diagnosis of prostate cancer with strong family history (2 or more first-degree or second-degree relatives) with prostate cancer (particularly metastatic prostate cancer or died from prostate cancer), breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, uterine cancer, renal cancer, urothelial cancer, or upper bowel cancer\n\nExclusion Criteria:\n\n* Patients that do not meet the inclusion criteria\n* Children under the age of 18\n* Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process",{"count":134,"type":21},"OBSERVATIONAL","This trial evaluates whether a network of peer genetic coaches is useful for addressing disparities in genetic testing and screening among African American men with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). While genetic testing has become central to prostate cancer care, African American men are less likely seek testing due to lack of awareness, cultural beliefs, financial limitations, fear of discrimination, and mistrust in the healthcare system. A network of peer genetic coaches may help address barriers, beliefs, and needs of African American men in the community and provide navigation to increase engagement in genetic testing.",[312,313,314,315],"Metastatic Prostate Carcinoma","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8",{"date":295,"type":44},{"date":318,"type":44},"2024-06-03",{"date":320,"type":21},"2026-09-30",{"name":50,"class":51},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":309,"phases":4,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":52},"100638879","spinal-dural-arteriovenous-fistula-international-data-and-outcomes-registry-100638879","NCT07574645","Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry","SPIDER - Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry","SPIDER","Inclusion Criteria:\n\n* Type 1 spinal dural arteriovenous fistula, confirmed on imaging\n* Surgically or endovascularly treated\n* At least 1 available primary outcome",{"count":331,"type":21},1000,"Given the lack of large multicenter datasets in the context of Spinal arteriovenous fistula, the strength of the evidence surrounding this rare disease is limited. SPIDER hence aims to address that by compiling patient-level data from centers all around the world.",[334],"Spinal Dural Arteriovenous Fistula",[336,337,338,339,340,341,342],"spinal dural arteriovenous fistula","spinal arteriovenous malformation","spinal AVF","sdAVF","international","multicenter","registry","2026-05-04",{"date":345,"type":44},"2026-05-08",{"date":347,"type":44},"2026-01-05",{"date":349,"type":21},"2026-05",{"name":50,"class":51},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":52},"100625042","phase-1-gucy2c-prime-boost-vaccination-for-advanced-colorectal-and-small-bowel-adenocarcinomas-100625042","NCT07417488","GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas","A Phase I, Single-Center, Dose Escalation Trial of Heterologous Prime-Boost Vaccination With Ad5.F35-hGUCY2C-PADRE and Lm-GUCY2C Vaccines in Adults With Advanced Colorectal and Small Bowel Adenocarcinomas","Inclusion Criteria:\n\n* Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:\n\n  1. Males or females aged ≥ 18 years\n  2. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n  3. Histologically or cytologically diagnosed, locally advanced or metastatic adenocarcinomas of colorectum or small bowel that have progressed after standard of care therapy or for which no standard therapy exists. Patients for whom standard therapies are intolerable or considered clinically inappropriate by the Investigator are eligible. If a patient refused available standard therapy or Investigator determined standard therapy was inappropriate, the reason for refusal or Investigator determination should be documented.\n  4. Patients with MSS CRC or small bowel adenocarcinoma must have received at least 1) a fluoropyrimidine, 2) oxaliplatin or irinotecan, and 3) a VEGF\u002FVEGF receptor inhibitor unless deemed clinically inappropriate, refused by the patient, or not considered standard practice per institutional standards.\n  5. Patients with MSI-H and\u002For dMMR CRC or small bowel adenocarcinoma must have received a programmed death-1 or programmed death-ligand 1 (PD-L1) inhibitor unless deemed clinically inappropriate, refused by the patient, or not considered standard practice.\n  6. Have an anticipated life expectancy of greater than 12 weeks\n  7. Have at least 1 extracranial measurable tumor lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Exceptions may be made to this inclusion if a patient has biochemical evidence (ctDNA) of disease upon discussion with principal investigator provided other eligilbity criteria are fulfilled.\n  8. Adequate venous access by peripheral vein evaluation\n  9. Have adequate hematologic function at screening, as evidenced by:\n\n     1. ANC ≥ 1500 cells\u002FmL; no growth factor support within 14 days prior to Screening assessment\n     2. Platelets ≥ 75,000 \u002FmL; no transfusion within 14 days prior to Screening assessment\n     3. Hemoglobin ≥ 9.0 g\u002FdL; no transfusion or erythyropoietin support within 14 days prior to Screening assessment.\n  10. Patients must have adequate hepatic function, as evidenced by:\n\n      1. Albumin ≥ 3.0 mg\u002FdL; no albumin support within 14 days prior to Screening assessment,\n      2. Total bilirubin ≤ 2.0 x upper limit of normal (ULN), except in patients with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤ 1.5 x ULN is required)\n      3. Aspartate aminotransferase (AST) AND alanine aminotransferase ≤ 2.5 x ULN or ≤ 5 x ULN in the presence of liver metastases.\n      4. Serum creatinine \\\u003C 2.0 mg\u002FdL\n      5. For other blood and urine tests including blood chemistry, hepatic and renal functions, test results should not be worse than grade 1 levels of abnormalities defined by CTCAE, NCI version 5 (CTCAEv5) issued by the US Department of Health and Human Services.\n  11. For women and men of childbearing potential, a medically acceptable method of highly effective contraception (oral hormonal contraceptive, condom plus spermicide, or hormonal implants) or abstinence must be used throughout the study period and for 28 days after their final vaccine administration. (A barrier method of contraception must be employed by all subjects \\[male and female\\], regardless of other methods unless abstinent.) A negative serum or urine pregnancy test is required as part of screening. Subjects capable of becoming pregnant include any female who has experienced menarche and has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and who are not postmenopausal. Also, subjects assigned female sex at birth who are physiologically still able to become pregnant by similar definitions detailed here. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU\u002Fml.\n  12. Be willing to comply with all the study procedures. All subjects must be able to comprehend and sign a written informed consent document\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. History of splenectomy\n  2. History of infection with listeriosis or has prior serious reaction to adenovirus\n  3. Infection requiring systemic antibiotics within 1 week prior to administration of study intervention\n  4. Concurrent use of systemic steroids or immunosuppressive drugs (including TNF pathway inhibitors) with exceptions including:\n\n     * Topical, ocular, intra-articular, intranasal, and inhalation corticosteroids (with minimal systemic absorption)\n     * Adrenal replacement steroid dose \\\u003C 10 mg daily prednisone\n     * A brief (fewer than three days) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction cause by a contrast allergen)\n  5. Subjects who have implanted medical devices that pose high risks for colonization and cannot be easily removed (e.g., artificial heart valves, pacemakers, prosthetic joints, orthopedic screw(s), metal plate(s)). Chest wall infus-a-port catheter may be used for treatment administration and will not be subject to this exclusion.\n  6. Has any immunodeficiency disease or immunocompromised state (e.g., use of immunosuppressive agents including TNF pathway inhibitors, chemotherapy, PI3 kinase inhibitors or radiation therapy within four weeks of study treatment)\n  7. Has active or history of autoimmune disease (including inflammatory bowel disease), or is a transplant recipient requiring immunosuppressive treatment\n  8. Has received a diagnosis of HIV, hepatitis B, or hepatitis C (subjects who are hepatitis C positive may be enrolled if they are confirmed with negative viral load at screening)\n  9. Other malignancy within last 2 years except curatively treated non-melanomatous skin cancer and curatively treated carcinoma in situ (eg, cervix, bladder, breast), or prostate cancer in remission\n  10. Known active central nervous system metastases and\u002For carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are:\n\n      1. Radiologically stable, ie, without evidence of progression for at least 12 weeks by repeat imaging\n      2. Clinically stable per investigator assessment\n      3. Without requirement of steroid treatment for at least 14 days prior to first dose of study vaccine\n  11. Has an intercurrent illness that is either life-threatening or of clinical importance such that it might limit study compliance (such illnesses include, but are not limited to, ongoing or active infection, metabolic or neurologic disease, peripheral vascular disease, or psychiatric illness)\n  12. Has insufficient peripheral venous access to permit completion of the study phlebotomy regimen or infusion of study vaccine\n  13. Concurrent use of illicit drugs (e.g., opioids, cocaine, amphetamines, hallucinogens, etc.) that could potentially interfere with adherence to study procedures or requirements.\n  14. Be pregnant or breastfeeding\n  15. Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to grade 1 or less or baseline except for the following Grade 2 AEs that are considered chronic or irreversible: alopecia, peripheral neuropathy, endocrinopathies stable on therapy, and thromboembolic events stable on anticoagulation with no recurrence for \\> 6 months. Other Grade 2 AEs may be permitted upon discussion with the PI if not otherwise specified in the protocol.\n  16. Are currently enrolled in an ongoing clinical trial or trial that could interfere with the protocol-specified requirements\n  17. There are no restrictions on concurrent or prior use of preventative vaccines for infectious diseases including influenza or COVID-19, however it is required to include at least one week interval between vaccines and study agent administration.",{"count":359,"type":21},18,[24],"This is an open-label, non-randomized, single-center, dose-escalation Phase 1 trial using a heterologous prime-boost strategy of vaccination with Ad5.F35-hGUCY2C-PADRE and recombinant Listeria monocytogenes (Lm-GUCY2C) vaccines in patients with advanced solid tumors including colorectal cancer, and small bowel adenocarcarcinomas who have progressed on available standard therapies. The study treatment will begin with Ad5.F35-hGUCY2C-PADRE vaccine administered intramuscularly (IM) once at the recommended Phase 2 dose (RPTD) dose, followed four weeks later by two administrations of Lm-GUCY2C intravenously (IV) at one of three escalating dose levels, four weeks apart. Treatment-related toxicity and development of immune responses will be evaluated every four weeks through week 8 after initial Lm-GUCY2C vaccination. Primary endpoints will include maximum tolerated dose (MTD) and safety and tolerability as measured by treatment emergent adverse events (TEAEs) and clinically significant changes in safety laboratory tests in the dose limiting toxicity (DLT) evaluation period defined as 4 weeks after the initial Lm-GUCY2C vaccination.",[363,364],"Colorectal Cancer","Small Bowel Adenocarcinoma",{"date":345,"type":44},{"date":367,"type":44},"2026-04-21",{"date":369,"type":21},"2028-04",{"name":50,"class":51},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":205,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":387,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":52},"100577343","breastfeeding-education-support-tool-100577343","NCT06797063","Breastfeeding Education Support Tool","BEST4Baby","Inclusion Criteria:\n\n* at least 18 years of age,\n* pregnant and 20-27 weeks of gestation at study enrollment,\n* singleton pregnancy,\n* no major antepartum complications,\n* living in a research site,\n* planning to deliver in the cluster area,\n* capable of giving informed consent,\n* willing to be visited by a PC and research personnel for up to 12 months post-delivery.\n\nExclusion Criteria:\n\ncomorbidities impacting breastfeeding,\n\n\\- severe psychological illness that could interfere with consent and study participation. Following a live birth, participants will remain eligible to continue in the study unless the mother or infant experiences: illness or clinical complications warranting prolonged hospitalization, stillbirth, low birth weight (\\\u003C 2500 g), congenital abnormality, or neonatal death.",{"count":379,"type":21},336,[210],"The proposed project seeks to evaluate the effectiveness and implementation of the Breastfeeding Education Support Tool for Baby (BEST4Baby) intervention, an mHealth-supported community-based peer counselor breastfeeding intervention for mothers in India. Given that rates of optimal infant feeding practices have remained stagnant over the past two decades in India, and that India is the most populous country and icontributes one-fifth of all global live births, this project could have major global health implications if the intervention is found to improve maternal breastfeeding practices and infant clinical outcomes. The project will also provide evidence needed to adopt BEST4Baby nationally and in other low resource communities.",[383,384,385,386],"Breastfeeding, Exclusive","Infant Development","Infant Growth","Breast Feeding",[388,389,390,391],"breastfeeding","India","infant feeding","peer counselors",{"date":393,"type":44},"2026-05-05",{"date":395,"type":21},"2026-09-01",{"date":397,"type":21},"2029-09-01",{"name":50,"class":51},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100635081","phase-2-effectiveness-of-dextrose-pleurodesis-for-the-management-of-post-operative-air-leak-100635081","NCT07548047","Effectiveness of Dextrose Pleurodesis for the Management of Post-Operative Air Leak","Dextrose Pleurodesis Versus Standard of Care for the Management of Post-Operative Air Leak: A Single Center Prospective Trial","Inclusion Criteria:\n\n* Adult patients who have undergone lung resection\n* Persistent post-operative air leak \\>24 hours after surgery with air leak \\>20 mL\u002Fmin\n\nExclusion Criteria:\n\n* pregnant patients\n* incarcerated patients\n* patients with early post-operative complications\n* hemodynamic instability\n* need for mechanical ventilator support\n* high volume chest tube output (\\>750 mL over 24h)",{"count":407,"type":21},80,[25],"A common complication following lung resection surgery is the presence of a post-operative air leak. This occurs when the resected lung tissue does not seal adequately, resulting in continued leakage of air from the lung. For most patient, an air leak will self-resolve by maintaining a drainage catheter in the chest for a prolonged period. However, for some patients, additional measures are required to help seal the affected tissue. Known strategies for managing post-operative air leak include placing one-way valves, surgical revision, and chemical pleurodesis. Chemical pleurodesis involves injecting an irritant through the chest drainage catheter to promote sealing of the leaking lung tissue. While many agents exist for chemical pleurodesis, a relatively new method for treating an air leak is by using dextrose solution. Dextrose is appealing due to low cost and availability. Dextrose solution has shown some efficacy in other countries and undergone Phase 1 clinical investigation in Canada to show its safety and dosing recommendations. In this study, our aim is to compare the effectiveness of using dextrose solution for treating post-operative air leak compared to usual care with chest tube drainage alone.",[411],"Post Operative Pulmonary Air Leak",[413,414,415,416],"dextrose","air leak","lung resection","pleurodesis","2026-04-20",{"date":419,"type":44},"2026-04-23",{"date":421,"type":21},"2026-06-01",{"date":423,"type":21},"2029-06-30",{"name":50,"class":51},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":204,"sex":17,"minAge":432,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":446,"locationsCount":4},"100633422","improving-dementia-care-in-primary-practice-100633422","NCT07526480","Improving Dementia Care in Primary Practice","IDC","Inclusion Criteria:\n\n* No previous diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD).\n* Have a scheduled PCP visit in the next 4-6 weeks\n* Have subjective cognitive impairment\n* Score ≥ 26 on the Telephone Interview for Cognitive Status (TICS)\n\nExclusion Criteria:\n\n* EHR evidence or previous cognitive evaluations, diagnosis of MCI or AD, or use of AD medications\n* TICS score of ≤ 11.00\n* Inability to provide informed consent","66 Years",{"count":407,"type":21},[210],"This clinical trial will evaluate a multi-level scalable intervention called Improving Dementia Care (IDC). The investigators hypothesize that IDC will increase dementia detection in patients with impaired cognition more than the control condition, Enhanced Usual Care (EUC), over 6 months.",[437,438,439],"Alzheimer Disease (AD)","Mild Cognitive Impairment (MCI)","Dementia","2026-04-14",{"date":442,"type":44},"2026-04-17",{"date":343,"type":21},{"date":445,"type":21},"2027-05-03",{"name":50,"class":51},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":454,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":52},"100626494","early-phase-1-application-of-contrast-enhanced-ultrasound-in-monitoring-soft-tissue-sarcoma-response-to-neoadjuvant-radiotherapy-100626494","NCT07436364","Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy","Inclusion Criteria:\n\n* Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:\n\n  * Provide signed and dated informed consent form\n  * Willing to comply with all study procedures and be available for the duration of the study\n  * Male or female, Male or female, aged ≥18 years of age\n  * Patients with pathologically confirmed STS (Trunk and extremity sarcoma only)\n  * Scheduled for neoadjuvant RT for STS\n\n    o Both standard and hypofractionation schedules are permitted.\n  * Willing to comply with all study procedures and be available for the duration of the study\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  * Pregnancy or lactation\n  * Known allergic reactions to any component of Definity\n  * Has STS that is too large for ultrasound imaging (e.g. its short axis is larger than 10 cm at the depth of 2 cm)\n  * Has other primary cancers requiring systemic treatment.\n  * Has metastatic disease at presentation\n  * Had prior RT to the area",{"count":282,"type":21},[455],"EARLY_PHASE1","This pilot study will evaluate the feasibility of applying CEUS as imaging guidance for planning RT and predicting RT response. The investigators will determine if US-CT\u002FMRI fusion is feasible and if tumor vascularity and pressure from CEUS can be used to reflect\u002Fpredict the RT response.\n\nThe investigators will perform CEUS three times: before the first neoadjuvant RT fraction, halfway through RT, and between the completion of RT and surgery. The fusion will be performed using previously acquired CT\u002FMRI or on-site cone-beam CT with Bmode US. Once the fusion is successful, CEUS will be performed and panoramic 2D images (mimicking 3D) will be collected for the whole tumor. If the fusion is not feasible or successful, the investigators will perform CEUS side by side with CT\u002FMRI and collect images. The investigators will quantify tumoral vascularity comparing Bmode area\u002Fvolume (total tumor) and contrast-enhanced area\u002Fvolume (vascular region) at each time point. Subharmonic amplitudes in the tumor area\u002Fvolume will be quantified to estimate tumoral pressure (known to be the same level as interstitial fluid pressure (IFP)). Quantified vascularity and pressure at each time point will be compared with the tumor size change at later study points as well as the histological outcome after the surgery.",[458],"Soft Tissue Sarcoma",[460,146,461,462,463,464,465,466,467,468,469],"Sarcoma","Ultrasound Imaging","Definity","ultrasound contrast agent","Subharmonic-aided Pressure Estimation","SHAPE","tumor vascularity","CT","MRI","on-site cone-beam CT","2026-04-09",{"date":440,"type":44},{"date":473,"type":44},"2026-03-23",{"date":475,"type":21},"2027-05",{"name":50,"class":51},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":181,"minAge":18,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":22,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":52},"100476738","peer-navigation-for-the-support-of-metastatic-prostate-cancer-patients-undergoing-genetic-evaluation-100476738","NCT05487846","Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation","ADVANTAGE: Addressing Disparities for Veterans and African Americans Through Peer-Navigation for Testing and Genetic Evaluation","Inclusion Criteria:\n\n* Provide signed and dated informed consent form\n* English speaking only\n* Willing to comply with all study procedures and be available for the duration of the study\n* Any individual \\>= 18 years old\n* African American men who meet National Comprehensive Cancer Network (NCCN) criteria for testing will be offered participation. These criteria include any one of the following: (1) metastatic prostate cancer (PCA); (2) intraductal or ductal pathology; (3) T3a or higher; (4) grade group 4 or Gleason 8 or higher; (5) family history of breast, ovarian, prostate, pancreatic, colorectal, or uterine cancers in 3 or more blood relatives particularly if diagnosed at age \\\u003C 50. These criteria have been adapted from the NCCN Prostate Cancer (version 2.2021) and NCCN Breast, Ovarian, and Pancreatic (version 2.2021) guideline\n\nExclusion Criteria:\n\n* Patients that do not meet the inclusion criteria and children under the age of 18 will be excluded\n* Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process will also be excluded",{"count":485,"type":21},120,[210],"This clinical trial evaluates whether having a trained peer navigator helps African American men with prostate cancer that has spread to other parts of the body (metastatic) understand and navigate the genetic testing process better than not having a peer navigator. Genetic testing for men with prostate cancer is very important for making treatment and management decisions. However, understanding the risks, benefits, and steps of genetic counseling and testing can be very challenging for patients. African American men are especially less likely to participant in genetic testing due to lack of awareness or understanding, cultural beliefs, finances, or mistrust of the healthcare system. A peer navigator, someone who helps a patient through the information and the process, may be helpful to some men. This study evaluates whether having a peer navigator throughout the genetic evaluation process helps patients understand and engage in the process more.",[312,489,315],"Stage III Prostate Cancer AJCC v8",{"date":440,"type":44},{"date":492,"type":44},"2025-01-01",{"date":494,"type":21},"2026-09",{"name":50,"class":51},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":512,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":52},"100631512","phase-1-pembrolizumab-plus-ultrasound-induced-microbubble-cavitation-in-head-and-neck-cancer-100631512","NCT07501650","Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer","Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:\n\n  1. Pathologically confirmed, HPV-negative, R\u002FM HNSCC per American Joint Committee on Cancer (AJCC) 8th Edition Staging Criteria, with CPS score \\> 1\n  2. The target lesion is ultrasound-accessible, biopsy-accessible, and measurable in at least one dimension, based on RECISTv1.1 criteria.\n  3. Male or female, aged ≥18 years of age\n  4. ECOG Performance status 0-2.\n  5. Must have a life expectancy of at least 6 months as judged by the treating physician.\n  6. Adequate organ function:\n\n     1. Absolute neutrophil count 1500\u002Fμl or more;\n     2. Platelets 100,000\u002Fμl or more,\n     3. Hemoglobin 8 g\u002Fdl or more;\n     4. Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin \\\u003C3 mg\u002Fdl);\n     5. AST and ALT less than or equal to 2.5x the upper limit of normal\n  7. Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of HCG), which must also be confirmed as negative within 28 days of the start of study drugs.\n  8. Women of reproductive potential must use highly effective contraception methods to avoid pregnancy for 90 days after the last dose of study drugs. \"Women of reproductive potential\" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, tubal ligation, or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU\u002FmL.\n  9. Men of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year. Men who are receiving the study medications will be instructed to adhere to contraception for 90 days after the last dose of study drugs. Men who are azoospermic do not require contraception.\n  10. Informed Consent: All subjects must be able to comprehend and sign a written informed consent document.\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Patients with HPV-positive or p16-positive SCC\n  2. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or antiCTLA-4 antibody\n  3. Any history of allergy to the study drug components, including to polyethyleneglycol or medications containing polyethylene glycol.\n  4. Patients with the following cardiac conditions or history:\n\n     1. Patients with a known history of anatomic right-to-left, bi-directional, or transient right-to-left cardiac shunts\n     2. Patients with NYHA class III or greater heart failure, unstable anginal syndrome, or experiencing active chest pain.\n     3. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg)\n     4. Patients who have experienced a STEMI or NSTEMI within the last 6 months\n     5. QTc \\>500 as determined by Fridericia correction\n     6. Patients with a history of ventricular arrhythmia that has not been corrected by placement of a PPM or ICD\n  5. Any concurrent malignancies: exceptions include- cutaneous basal cell carcinoma, chronic lymphocytic leukemia, melanoma in situ, squamous cell carcinoma of the skin of a secondary location, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy. Patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 2 years post-diagnosis.\n  6. Any unresolved toxicity CTCAEv5.0 Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. Patients with Grade ≥2 neuropathy will be evaluated on a caseby-case basis after consultation with the Study Physician. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with anti-PD-1 therapy may be included only after consultation with the Study Physician.\n  7. Any subjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 28 days of study drug administration., or a prior history of allogenic organ transplantation.\n  8. Any active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n  9. Patients must not be receiving any other investigational agents; must not have participated in a study of an investigational agent or be using an investigational device within 4 weeks of the first dose of Pembrolizumab plus Definity.\n  10. Receipt of a live attenuated vaccine within 30 days prior to the first dose of drug on trial.\n  11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n  12. Patients must not be pregnant or breastfeeding.\n  13. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1\u002F2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\]and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCVRNA.\n  14. Any untreated metastasis(es) to the brain that may be considered active.\n  15. History of pneumonitis within the past 5 years.",{"count":504,"type":21},6,[24],"This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab) among patients with R\u002FM HNSCC, delivered with ultrasound-induced microbubble cavitation, with the goal of optimizing delivery of Pembrolizumab and tumor response to Pembrolizumab. Patients will undergo 3 infusions of Pembrolizumab plus Definity 3 weeks apart. Following each infusion, ultrasound will be directed at the primary tumor site to induce microbubble cavitation, with the goal of tumor sonoporation. The primary endpoints will be feasibility, measured based on successful recruitment of 6 participants within 1 year of initiating recruitment, with successful completion of trial procedures among at least 80 percent of patients. Secondary endpoints will include proportion of serious adverse events, clinical\u002Fradiographic response, overall survival, and progression-free survival.",[508,509,510,511],"Head and Neck Cancer","Head and Neck Small Cell Carcinoma","Metastatic Head and Neck Cancer","Recurrent Head and Neck Cancer",[513,514,515,516,517],"Recurrent","Pembrolizumab","Pembro","Microbubble","Cavitation","2026-03-24",{"date":520,"type":44},"2026-03-30",{"date":522,"type":44},"2026-03-18",{"date":524,"type":21},"2028-03",{"name":50,"class":51},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":22,"phases":535,"briefSummary":536,"conditions":537,"keywords":541,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":52},"100609992","preoperative-opioid-tapering-before-spine-surgery-100609992","NCT07221786","Preoperative Opioid Tapering Before Spine Surgery","A Pilot Study of the Feasibility of Preoperative Opioid Tapering Before Spine Surgery Using Cognitive Behavioral Therapy and Measuring Postoperative Outcomes","Inclusion:\n\n* at least 18 years old\n* scheduled for major spine surgery (i.e. at least 1 level of fusion) with hospital admission of at least one night\n* scheduled for spine surgery at least 4 weeks ahead of time\n* takes between 40 and 200 oral morphine equivalents daily\n\nExclusion:\n\n* inability to use a computer or tablet for telemedicine encounters\n* non-English-speaking\n* inability to complete assessments\n* positive screen on the Columbia Suicide Screening Assessment",{"count":534,"type":21},45,[210],"This is a pilot study in which patients taking opioids chronically who are scheduled for spine surgery at least 4 weeks in advance will be randomly assigned to one of two groups: opioid tapering with education alone or opioid tapering with education plus cognitive behavioral therapy (CBT). The primary objective is to determine the proportion of each group that is successful in achieving their opioid tapering goals by the time of surgery.",[538,539,540],"Opioid Consumption, Postoperative","Pain After Surgery","Opioid Dependency",[542,543,544,545,546,547,548,549,550],"spine surgery","pain management","opioids","opioid use","depression","anxiety","opioid dependence","opioid tapering","cognitive behavioral therapy",{"date":518,"type":44},{"date":553,"type":44},"2025-12-01",{"date":555,"type":21},"2026-12",{"name":50,"class":51},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":205,"minAge":18,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":309,"phases":4,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":52},"100629695","exploring-inflammation-and-social-determinants-study-in-breast-cancer-patients-100629695","NCT07478016","EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients","EXploring Inflammation and Social deTerminants (EXIST) Study in Breast Cancer Patients","EXIST","Inclusion Criteria:\n\n* Individuals must meet all the following inclusion criteria to be eligible to participate in the study:\n\n  1. Female\n  2. \\>18 years old at time of consent\n  3. Biopsy proven invasive breast cancer or ductal carcinoma in situ\n  4. Candidate has not yet received cancer therapy for their breast cancer diagnosis\n  5. ECOG Performance Status \\\u003C 2\n  6. Able to provide consent\n  7. Must be English speaking\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Patient has started therapy or already had definitive oncologic surgery\n  2. Another malignancy within the past 6 months that was not a non-melanomatous skin lesion",{"count":566,"type":21},200,"This is a pilot trial to assess how measures of inflammation are correlated with Social Determinants of Health (SDoH) in breast cancer patients. Expected duration of subject participation is one single time point. The patients will fill out questionnaires and provide a plasma sample.",[569,570],"Breast Cancer","Ductal Carcinoma In Situ",[572,573,574,575],"Social Determinants of Health","IL-6","cytokine profile","immune marker profile","2026-03-13",{"date":578,"type":44},"2026-03-17",{"date":580,"type":44},"2022-12-21",{"date":582,"type":21},"2028-12-31",{"name":50,"class":51},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":52},"100487449","phase-1-tazemetostat-and-palbociclib-with-cpx-351for-rr-aml-100487449","NCT05627232","Tazemetostat and Palbociclib With CPX-351for R\u002FR AML","A Two-Part Phase 1b Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib Pre-Treatment Followed by CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Provide signed and dated informed consent form\n* Willing to comply with all study procedures and be available for the duration of the study\n* Male or female \\>= 18 years of age\n* Histologically confirmed acute myeloid leukemia (non-M3) relapsed from or refractory to at least 1 prior line of therapy. Bone marrow aspirate and biopsy within 28 days of screening is acceptable. If no prior bone marrow biopsy is available, bone marrow biopsy must be performed during screening unless:\n\n  \\* If the subject has \\>= 20% myeloblasts present in the peripheral blood, a bone marrow biopsy is not necessary to meet this criterion\n* Treatment with a prior investigational agent is acceptable so long as it has not been administered within 2 weeks of enrollment and any prior adverse effects have resolved to grade 1 or less with the exception of alopecia\n* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less\n* Life expectancy of at least 4 weeks\n* Must be able to consume oral medication\n* Subjects must have recovered from the toxic effect of any prior therapy to =\\\u003C grade 1 (except alopecia)\n* Creatine clearance (CrCL) \\>= 45\n* Total bilirubin \\\u003C 2 x upper limit of normal (ULN)\n* Female subjects of childbearing age must have a negative pregnancy test\n\nExclusion Criteria:\n\n* Subjects with acute promyelocytic leukemia\n* Subjects receiving any active chemotherapy agents (except hydroxyurea). Intrathecal methotrexate and cytarabine are permissible\n* Subjects whose participation would result in a total cumulative dose of daunorubicin greater than 550 mg\u002Fm\\^2 or greater than 450 mg\u002Fm\\^2 if they previously received mediastinal radiation\n* Subjects with evidence of active central nervous system (CNS) leukemia involvement. Lumbar puncture is not required for enrollment in the absence of neurologic symptoms\n* Subjects must not be receiving growth factors (except erythropoietin)\n* Subjects with currently active second malignancy with the exception of nonmelanoma skin cancer, carcinoma in situ of the cervix, resected prostate cancer with Gleason score =\\\u003C 6\n* Subjects with unstable cardiac disease or uncontrolled arrhythmia\n* Subjects with other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate to receive high-intensity therapy\n* Subjects who are pregnant or breastfeeding\n* Subjects with known allergic reactions to components of the study product(s)\n* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study",{"count":592,"type":21},24,[24],"This is a two-part phase Ib dose escalation study to evaluate the safety and preliminary efficacy of the combination of tazemetostat and CPX-351 (Part 1) and of pre-treatment with palbociclib followed by CPX-351 (Part 2) for patients with relapsed or refractory (R\u002FR) acute myeloid leukemia (AML). Part 1 of the study will seek to establish the safety, tolerability, biological activity and recommended dose for further evaluation (RDFE) of tazemetostat in combination with standard-dose CPX-351. Part 2 of the study will seek to establish the safety, tolerability, biological activity RDFE of pre-treatment palbociclib prior CPX-351.",[596,597],"Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","2026-03-10",{"date":600,"type":44},"2026-03-12",{"date":602,"type":44},"2023-08-28",{"date":604,"type":21},"2029-01",{"name":50,"class":51},{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":620,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":52},"100626493","act-with-cf-self-help-toolkit-100626493","NCT07436351","ACT With CF Self-Help Toolkit","Inclusion Criteria:\n\n* 18 years or older\n* Existing diagnosis of cystic fibrosis\n* PHQ-9 score \\>4 or GAD-7 score \\>4\n\nExclusion Criteria:\n\n* History of suicide attempts or acute suicidal ideation on clinical assessment\n* Presence of psychotic disorder or symptoms\n* Presence of psychiatric disorders that interfere with participation in the study, judged by the study or treating clinician\n* Presence of other medical conditions that interfere with participation in the study, judged by the study or treating clinician",{"count":613,"type":21},60,[210],"Acceptance and Commitment Therapy (ACT) tailored to meet the needs of adults living with cystic fibrosis (ACT with CF) is a newer form of talk therapy that has been shown to reduce anxiety \\& depression and improve psychological flexibility, and value-based living. The investigators are now trying to find out whether a self-help version of this treatment (ACT with CF - Self Help Toolkit) is also effective in reducing anxiety and depression and improving psychological flexibility and value-based living in adults with CF.\n\nAdults with cystic fibrosis are at increased risk for anxiety and depression. This study examines whether a patient-facing therapy, ACT with CF - Self Help Toolkit can help to reduce anxiety and depression among adults with CF. This treatment can be accessed on the participant's smartphone.",[617,618,619],"Cystic Fibrosis (CF)","Depressive and Anxiety Disorders","Psychological Flexibility",[621,622,623,624],"cystic fibrosis","ACT","CF","chronic illness","2026-02-27",{"date":627,"type":44},"2026-03-03",{"date":629,"type":44},"2026-01-20",{"date":631,"type":21},"2027-04",{"name":50,"class":51},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":640,"enrollmentInfo":641,"targetDuration":4,"studyType":22,"phases":643,"briefSummary":644,"conditions":645,"keywords":652,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":91},"100611006","clinical-trial-to-evaluate-post-operative-outcomes-of-ureteral-stent-vs-ureteral-stent-free-radical-cystectomy-100611006","NCT07234968","Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy","Randomized Controlled Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy","Inclusion Criteria:\n\n* Individuals must meet all the following inclusion criteria to be eligible to participate in the study:\n\n  * Provide signed and dated informed consent form\n  * Willing to comply with all study procedures and be available for the duration of the study\n  * Male or female, age 18 to 85\n  * Diagnosed with bladder cancer, other pelvic malignancies necessitating a cystectomy (e.g.: colorectal, prostate, gynecologic) and have elected for a cystectomy with ileal conduit urinary diversion\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  * Current or history of pelvic radiation\n  * Retroperitoneal fibrosis\n  * Untreated urinary tract infection (UTI) within 30 days prior to RCIC\n  * Pregnancy","85 Years",{"count":642,"type":21},70,[210],"Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op. Risk of post-op complications will be analyzed.",[646,647,648,649,650,651],"Bladder Cancer","Muscle-Invasive Bladder Carcinoma","Urothelial Carcinoma","Pelvic Malignancy","Bladder Transitional Cell Carcinoma","Bladder Neoplasm",[653,654,655,656,657,649,646,658,659,660,661,662,663,664,665,666,667,668],"Bladder","Stent-free Cystectomy","Urinary Tract Infection","Urinary Leak","UTI","Urologic Oncology","Muscle-invasive Bladder Cancer","indocyanine green","fluorescence imaging","ureteral stents","RCIC","cystectomy","colorectal","prostate","gynecologic","ileal conduit urinary diversion","2026-02-12",{"date":671,"type":44},"2026-02-17",{"date":673,"type":44},"2025-12-23",{"date":675,"type":21},"2028-04-30",{"name":50,"class":51},{"id":678,"slug":679,"hasResults":12,"nctId":680,"briefTitle":681,"officialTitle":682,"acronym":4,"eligibilityCriteria":683,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":684,"targetDuration":4,"studyType":22,"phases":686,"briefSummary":687,"conditions":688,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":690,"startDateStruct":691,"completionDateStruct":693,"leadSponsor":694,"locationsCount":52},"100441710","virtual-reality-3d-surgery-modeling-to-enhance-head-and-neck-cancer-surgery-quality-100441710","NCT05031910","Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality","Preoperative Virtual Reality and 3D Pathologic Modeling as Treatment for Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Diagnosed with cancer of the head and neck (oral cavity, oropharynx, larynx, hypopharynx, T1-T4)\n* Receiving treatment at Thomas Jefferson University - Center City by a fellowship-trained HNC surgeon\n* Eligible for definitive resection\n* Age \\> 18\n* Provide signed written informed consent document\n\nExclusion Criteria:\n\n* Impaired judgement or those unable to provide informed consent\n* Any factor that would place the patient at increased risk or preclude the individual's full compliance with or completion of the study\n* Nasopharyngeal carcinoma\n* Contraindications for surgery\n* Enrollment in other clinical trial",{"count":685,"type":21},160,[210],"This clinical trial studies the use of virtual reality technology and three dimensional surgery (3D-surgery) modeling to enhance current treatments in head and neck cancer surgery. Virtual reality 3D-surgery modeling may improve quality of surgical planning and interdisciplinary communication between surgeons and pathologists during the treatment of head and neck squamous cell cancer and ultimately increase the accuracy of planning, the quality of communication, and maximize the outcome patients with head and neck cancer experience throughout treatment.",[689],"Head and Neck Squamous Cell Carcinoma",{"date":671,"type":44},{"date":692,"type":44},"2022-02-04",{"date":475,"type":21},{"name":50,"class":51},{"id":696,"slug":697,"hasResults":12,"nctId":698,"briefTitle":699,"officialTitle":699,"acronym":4,"eligibilityCriteria":700,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":701,"targetDuration":4,"studyType":309,"phases":4,"briefSummary":703,"conditions":704,"keywords":705,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":714,"lastUpdatePostDateStruct":715,"startDateStruct":716,"completionDateStruct":718,"leadSponsor":719,"locationsCount":52},"100620050","from-screening-to-support-a-multi-method-analysis-of-hrsn-integration-in-cancer-care-100620050","NCT07352579","From Screening to Support: A Multi-Method Analysis of HRSN Integration in Cancer Care","Inclusion Criteria:\n\n* Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:\n\n  * Provide informed consent via check box for survey\n  * Provide verbal consent via Zoom for interview\n  * Must be able to read and understand English\n  * Willing to comply with all study procedures and be available for the duration of the study\n  * Patients with existing HRSN data in their EHR that answere4d yes to risk in at least one domain and no to wanting help\u002Ffollow up\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  * If they do not consent\n  * Non-patients with existing HRSN data in their EHR\n  * Individuals unable to complete the survey due to language barriers or other cognitive limitations",{"count":702,"type":21},500,"This observational study aims to identify the factors that influence whether cancer patients accept or decline supportive care services after screening positive for health-related social needs (HRSNs) at the Sidney Kimmel Comprehensive Cancer Center.\n\nThe study focuses on adult oncology patients who previously reported at least one HRSN-such as transportation, food, housing, or utility needs-but declined assistance when it was offered.\n\nThe main questions it aims to answer are:\n\n* What factors shape cancer patients' intentions to use supportive care services for HRSNs?\n* Why do patients who screen positive for HRSNs choose not to accept help offered by the healthcare system?\n\nParticipants will:\n\n* Complete a one-time electronic survey delivered via MyChart or email.\n* Optionally participate in a semi-structured Zoom interview (for a subset of 20-30 survey respondents) to explore decision-making in greater depth.",[241],[706,707,708,709,710,711,712,713],"Health-Related Social Needs","HRSNs","transportation access","food insecurity","housing instability","utility needs","Survey","Interview","2026-02-10",{"date":669,"type":44},{"date":717,"type":44},"2025-12-11",{"date":123,"type":21},{"name":50,"class":51},""]